风湿免疫科

订阅

MedSci主页/所有栏目/风湿免疫科

耀斑反应性水凝胶治疗关节炎

2018-04-07MedSciMedSci原创

关节炎 耀斑 水凝胶
关注

关节炎症状往往不可预测且常常突然恶化，这些事件使得炎症性关节炎（包括类风湿性关节炎和银屑病关节炎）的处理对患者和医生都极具挑战性

关节炎症状往往不可预测且常常突然恶化，这些事件使得炎症性关节炎（包括类风湿性关节炎和银屑病关节炎）的处理对患者和医生都极具挑战性。但伯明翰妇女医院（BWH）的研究人员发现，耀斑可能也是改善患者治疗方案的重要机会。在实验室进行的研究中，BWH生物工程师开发了一种水凝胶，这是一种柔韧的材料，可以装载关节炎药物并局部注入发炎关节。水凝胶并非以稳定的速率持续输送药物，而是设计用来对疾病的耀斑活动增加作出反应，即当症状恶化时释放药物。该团队的研究结果本周在Nature Communications上发表，研究人员正在努力将这一技术推向临床。

BWH的生物工程师兼首席研究员Jeff Karp博士说，“关节炎代表了巨大的未满足的临床需求，尽管已经开发出新的治疗方法，但许多方案具有全身毒性。williamhill asia 希望设计一种高效的输送系统，可以输送药物并释放药物来应对炎症”。新的耀斑响应性水凝胶由三甘油单硬脂酸酯（TG-18）制成，该化合物是美国食品和药物管理局认定的“公认安全”化合物的一种，TG-18是一种能够自组装的分子，意味着它可以形成包含纤维的凝胶状结构。在本研究中，TG-18水凝胶装载了曲安奈德（TA），但TG-18可能装载多种类型的抗炎化合物。


原始出处：

https://www.europeanpharmaceuticalreview.com/news/74244/flare-responsive-hydrogel-arthritis/

本文系williamhill asia 医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于williamhill asia 医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章，或“williamhill asia 号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系，williamhill asia 将立即进行删除处理。
在此留言
评论区(4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022811, encodeId=2c8120228116e, content=#反应性#, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Sep 24 16:27:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265675, encodeId=6db812656e577, content=#关节炎#, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Mon Apr 09 11:27:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308013, encodeId=bc351308013bb, content=#水凝胶#, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Apr 09 11:27:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460958, encodeId=13291460958e1, content=#凝胶#, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Mon Apr 09 11:27:00 CST 2018, time=2018-04-09, status=1, ipAttribution=)]
    2018-09-24 12499e01m47暂无昵称

    #反应性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2022811, encodeId=2c8120228116e, content=#反应性#, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Sep 24 16:27:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265675, encodeId=6db812656e577, content=#关节炎#, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Mon Apr 09 11:27:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308013, encodeId=bc351308013bb, content=#水凝胶#, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Apr 09 11:27:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460958, encodeId=13291460958e1, content=#凝胶#, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Mon Apr 09 11:27:00 CST 2018, time=2018-04-09, status=1, ipAttribution=)]
    2018-04-09 lmm397

    #关节炎#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2022811, encodeId=2c8120228116e, content=#反应性#, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Sep 24 16:27:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265675, encodeId=6db812656e577, content=#关节炎#, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Mon Apr 09 11:27:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308013, encodeId=bc351308013bb, content=#水凝胶#, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Apr 09 11:27:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460958, encodeId=13291460958e1, content=#凝胶#, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Mon Apr 09 11:27:00 CST 2018, time=2018-04-09, status=1, ipAttribution=)]
    2018-04-09 tastas

    #水凝胶#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2022811, encodeId=2c8120228116e, content=#反应性#, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon Sep 24 16:27:00 CST 2018, time=2018-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265675, encodeId=6db812656e577, content=#关节炎#, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Mon Apr 09 11:27:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308013, encodeId=bc351308013bb, content=#水凝胶#, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Apr 09 11:27:00 CST 2018, time=2018-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460958, encodeId=13291460958e1, content=#凝胶#, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Mon Apr 09 11:27:00 CST 2018, time=2018-04-09, status=1, ipAttribution=)]
    2018-04-09 lishizhe

    #凝胶#

    0

相关威廉亚洲官网

Nat Commun：根据小鼠关节炎发作情况响应的释药凝胶

本周《自然-通讯》论文Towards an arthritis flare-responsive drug delivery system发表一种小鼠模型，展示了一种响应炎症性关节炎的疾病活动性的释药凝胶。

11岁女童左肩疼痛 是关节炎还是另有元凶

（1）病历介绍：患者，女，11岁，主因左肩部疼痛3个月，门诊入院。患者于3个月前无明显诱因出现左肩部疼痛，疼痛为持续性，以关节炎治疗，无效。于两周前摄片发现左肱骨头病变。

Rheumatology：治疗幼年特发性关节炎患儿，TNF-α抑制剂vs DMARD

2018年2月，发表于《Rheumatology (Oxford)》上的一项研究，考察了与DMARD相比，TNF-α抑制剂（TNFI）的使用会为幼年特发性关节炎（JIA）患儿带来较高的严重感染风险。

常被误诊为关节炎的膝部疼痛

患者，男，21岁，主因左膝部疼痛半年，门诊收入院。患者于半年前无明显诱因出现左膝部疼痛，疼痛于活动时出现，休息时消失，未做特殊处理。于两周前检查后发现左股骨远端病变。

《玻璃酸钠在骨科和运动医学相关疾病中的应用专家共识（2017 年修订版）》解读

2017 年11 月，《玻璃酸钠在骨科和运动医学相关疾病中的应用专家共识（2017 年修订版）》正式发布，该共识对玻璃酸钠的来源、作用机制、药物代谢、安全性、不良反应、适应证、禁忌证等方面进行了全面修订，其中作用机制、适应证等内容修改幅度较大，更为适用和细化。本文就其重要更新内容进行简介和解读。

痛风增加化脓性关节炎风险

美国哈佛医学院麻省总医院风湿科的Sian Yik Lim和波士顿大学医学院的Na Lu、Hyon K. Choi在英国普通人群中开展的一项回顾性队列研究显示，成年人中的痛风会增加化脓性关节炎发病风险。